Prostate Cancer - docetaxel - MSI-H + MSH2 expression + MSH6 expression

Association details:

Biomarker:	MSI-H + MSH2 expression + MSH6 expression
Cancer:	Prostate Cancer
Drug:	docetaxel (Tubulin polymerization promoter, Microtubule stabilizer)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C4 – Case Studies

Source:

J Med Case Rep

Title:

Unexpected tumor response to palliative pelvic radiotherapy in mismatch repair-deficient advanced prostate cancer: a case report

Published date:

12/08/2020

Excerpt:

We report a 76 year-old Italian male patient presenting with locally advanced undifferentiated prostate cancer (LAPC), infiltrating bladder and rectum. Molecular analysis revealed high-MSI with an altered expression of MSH2 and MSH6 at immunohistochemistry. Two months after 6 chemotherapy cycles with Docetaxel associated to an LHRH analogue, a computed tomography scan showed stable disease.

DOI:

10.1186/s13256-020-02578-4